Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 3Lymphoid 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 9Lymphoma, Large B-Cell, Diffuse 8Breast Neoplasms 8Lymphoma, Follicular 6Neoplasms 5Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Endometrial Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Hodgkin Disease 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neoplasms × copanlisib × Clear all
NCT03474744 2026-05-06

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

University of Ulm

Phase 2 Active not recruiting
36 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT04042051 2025-07-22

Panthera

Cancer Trials Ireland

Phase 1 Terminated
2 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01411410 2017-10-11

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Bayer

Phase 1 Completed
55 enrolled
Tumor-Agnostic

Neoplasms

NCT00962611 2017-10-06

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Bayer

Phase 1 Completed
57 enrolled
Tumor-Agnostic

Neoplasms

NCT01392521 2015-04-17

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Bayer

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡